Science Explorer Back to mapMap
Discussion
Institution · Linear Clinical Research

Most cited papers from Linear Clinical Research

Linear Clinical Research

What are the most cited papers from Linear Clinical Research?

The most cited paper from Linear Clinical Research is "Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study" (Anthony R. Mato et al., 2021), with 471 citations. Next come "Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study" (462) and "Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial" (284).

Showing 50 of 60 papers. Every paper with more than 25 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study Anthony R. Mato et al. · The Lancet Open access Mar 2021 471
2 Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study Lihua Elizabeth Budde, Laurie Helen Sehn, Matthew J. Matasar et al. · The Lancet Oncology Open access 5 Jul 2022 462
3 Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial Peter Richmond, Lara Hatchuel, Min Dong et al. · The Lancet Open access 29 Jan 2021 284
4 Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia Anthony R. Mato et al. · New England Journal of Medicine Open access 5 Jul 2023 232
5 Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study David M. O'Malley, Maryna Neffa, Bradley J. Monk et al. · Journal of Clinical Oncology Open access 21 Dec 2021 192
6 Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors Jayesh Desai et al. · Journal for ImmunoTherapy of Cancer Open access Jun 2020 150
7 Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies Gautam Goel et al. · ˜The œLancet. Gastroenterology & hepatology Open access 11 May 2017 146
8 Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Mengzhao Wang et al. · Cancer Discovery Open access 11 Apr 2022 126
9 Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma Michael Wang et al. · Journal of Clinical Oncology Open access 16 May 2023 119
10 Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial Michael Leonard Friedlander, Tarek M. Meniawy, Ben Markman et al. · The Lancet Oncology Aug 2019 117
11 Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors Jayesh Desai et al. · Journal of Clinical Oncology Open access 17 Mar 2020 115
12 Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial Man‐Fung Yuen, Kosh Agarwal, Edward John Gane et al. · ˜The œLancet. Gastroenterology & hepatology Open access 9 Nov 2019 110
13 Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB Man‐Fung Yuen et al. · Journal of Hepatology Open access 20 Jul 2022 106
14 A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers Patrick F. Smith, Janakan Krishnarajah, Philip A. Nunn et al. · British Journal of Clinical Pharmacology Open access 21 Jun 2017 105
15 A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours Keith S. Dredge, Todd V. Brennan, Edward Hammond et al. · British Journal of Cancer Open access 9 Mar 2018 102
16 Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma Nancy L. Bartlett et al. · Blood Advances Open access 17 Apr 2023 99
17 Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor–Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors Kimberley M. Heinhuis, Matteo Salvatore Carlino, Markus Joerger et al. · JAMA Oncology Open access 7 Nov 2019 93
18 Scaling phrase-based statistical machine translation to larger corpora and longer phrases Chris Callison-Burch, Colin Bannard, Josh E. Schroeder Conference paperOpen access 2005 90
19 Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients Matthew R. Wilson et al. · Blood Open access 7 Jan 2022 89
20 Burkitt Lymphoma International Prognostic Index Adam J. Olszewski et al. · Journal of Clinical Oncology Open access 27 Jan 2021 87
21 Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-naïve adults Susan B. Manoff, Michele Sausser, Amy Falk Russell et al. · Human Vaccines & Immunotherapeutics Open access 14 Nov 2018 73
22 PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a) Gerald F. Watts, Dick C. Chan, Jing Pang et al. · Metabolism 30 Mar 2020 71
23 The Australian Desert Fireball Network: a new era for planetary science P. A. Bland, Pavel Spurný, A. W. R. Bevan et al. · Australian Journal of Earth Sciences Open access Mar 2012 68
24 Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review Edward Bataillard, Chan Yoon Cheah, Matthew J. Maurer et al. · Blood Advances ReviewOpen access 7 May 2021 67
25 First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity Hui Kong Gan, Michael Millward, Hua Ye et al. · Clinical Cancer Research 5 Apr 2019 66
26 Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial D. D. Kim, Janakan Krishnarajah, Stephen Lillioja et al. · Diabetes Obesity and Metabolism 3 Mar 2015 63
27 Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase David G. Warnock, Daniel Georges Bichet, Myrl D. Holida et al. · PLoS ONE Open access 7 Aug 2015 63
28 Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study Lihua Elizabeth Budde, Sarit E. Assouline, Laurie Helen Sehn et al. · Journal of Clinical Oncology Open access 28 Mar 2024 61
29 Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial Sarit E. Assouline, Won Seog Kim, Laurie Helen Sehn et al. · Blood 5 Nov 2020 59
30 YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial Timothy Anthony Yap, David J. Kwiatkowski, Ibiayi Dagogo‐Jack et al. · Nature Medicine 19 Oct 2025 58
31 Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy Afaf Abed, Leslie Calapre, Johnny Lo et al. · Journal for ImmunoTherapy of Cancer Open access Nov 2020 58
32 Non-Covalent BTK Inhibitors—The New BTKids on the Block for B-Cell Malignancies Katharine Louise Lewis, Chan Yoon Cheah · Journal of Personalized Medicine Open access 3 Aug 2021 57
33 Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168) Timothy D. Owens, Patrick F. Smith, Andrew David Redfern et al. · Clinical and Translational Science Open access Nov 2021 53
34 Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience Katharine Louise Lewis, Collin K. Chin, Kate Manos et al. · British Journal of Haematology Open access 16 Jul 2020 52
35 AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors Sophia Frentzas, Steven Kao, Rang Gao et al. · Journal for ImmunoTherapy of Cancer Open access Oct 2023 51
36 High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma Katharine Louise Lewis et al. · Journal of Clinical Oncology Open access 5 Oct 2023 49
37 An Inactivated Ross River Virus Vaccine Is Well Tolerated and Immunogenic in an Adult Population in a Randomized Phase 3 Trial Nina Wressnigg, Maikel V. W. van der Velden, Daniel Portsmouth et al. · Clinical and Vaccine Immunology Open access 24 Dec 2014 47
38 A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors Hui Kong Gan, Michael Millward, Mathilde Jalving et al. · The Oncologist Open access 15 Jun 2021 46
39 The longest-lived spider: mygalomorphs dig deep, and persevere Leanda Denise Mason, Grant Wardell‐Johnson, Barbara York Main · Pacific Conservation Biology Open access 19 Apr 2018 44
40 A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors Sophia Frentzas, Hui Kong Gan, Rasha Cosman et al. · Cell Reports Medicine Open access 17 Oct 2023 43
41 Egg-Derived Anti-SARS-CoV-2 Immunoglobulin Y (IgY) With Broad Variant Activity as Intranasal Prophylaxis Against COVID-19 Lyn R. Frumkin et al. · Frontiers in Immunology Open access Jun 2022 42
42 Modulation of the hypothalamic–pituitary–adrenal (HPA) axis by plants and phytonutrients: a systematic review of human trials Adrian L. Lopresti, Stephen James Smith, Peter D. Drummond · Nutritional Neuroscience Review 2 Mar 2021 41
43 Statin myopathy: the fly in the ointment for the prevention of cardiovascular disease in the 21st century? Helen Isobel Keen, Janakan Krishnarajah, Timothy R. Bates et al. · Expert Opinion on Drug Safety 12 Jul 2014 41
44 Clinical Study of Single‐Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients With Chronic Hepatitis B Edward John Gane et al. · Hepatology Open access 26 May 2021 40
45 Plant-based Medicines (Phytoceuticals) in the Treatment of Psychiatric Disorders: A Meta-review of Meta-analyses of Randomized Controlled Trials: Les médicaments à base de plantes (phytoceutiques) dans le traitement des troubles psychiatriques: une méta-revue des méta-analyses d’essais randomisés contrôlés Jerome J. Sarris, Wolfgang Marx, Melanie M. Ashton et al. · The Canadian Journal of Psychiatry Open access 18 Feb 2021 40
46 Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study William G. Wierda et al. · The Lancet Haematology 18 Jul 2024 38
47 ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study Charlotte Lemech, Ganessan Kichenadasse, Jens‐Peter Marschner et al. · Oncogene Open access 23 Dec 2022 38
48 A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia Jason D. Lickliter, Hui Kong Gan, Mark Voskoboynik et al. · Drug Design Development and Therapy Open access Mar 2020 37
49 Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy Afaf Abed, Ngie Law, Leslie Calapre et al. · European Journal of Cancer Open access 24 Jun 2022 36
50 Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia Michele Stanchina, Skye Montoya, Alexey Valeryevich Danilov et al. · Nature Reviews Clinical Oncology Review Nov 2024 33

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.